Cough virus kills liver cancer cells and hepatitis virus

November 15, 2016

A virus that causes childhood coughs and colds could help in the fight against primary liver cancer, according to a study.

Reovirus stimulates the body's own immune system to kill off the cancerous cells, the researchers at the University of Leeds found.

In addition, Reovirus is able to kill off the hepatitis C virus - a common cause of primary liver cancer - at the same time, the team discovered.

These early-stage findings are important because primary liver cancer is the third highest cause of cancer deaths worldwide and, if surgery is not an option, the prognosis is poor.

Study co-leader Dr Stephen Griffin, Associate Professor of Viral Oncology at the University of Leeds, said: "Ultimately we hope that by simultaneously treating the tumour, and the hepatitis virus that is driving the growth of the tumour, we may provide a more effective therapy and improve the outcomes for patients.

"Current treatments for liver cancer that can't be removed by surgery are mainly palliative - with chemotherapy only tending to prolong life, rather than cure - and it can have significant side effects."

Reovirus can cause respiratory illnesses and stomach upsets in children but by adulthood most people have been exposed to it and therefore it does not cause illness.

The University of Leeds team, whose study is published today in the journal Gut, found that Reovirus was successful in treating both liver cancer cells grown in the laboratory and those taken directly from patients undergoing surgery.

When introduced into the body, Reovirus stimulates an immune system factor known as interferon, which in turn causes the activation of a specific white blood cell called a Natural Killer cell.

These Natural Killer cells then kill both the tumour, and cells infected with the hepatitis C virus.

Stimulating the immune system to kill cancer cells is known as immunotherapy. It differs from chemotherapy, in which the actual drugs kill the cancer cells.

The researchers are now hoping to start the first in-human clinical trials.

Study co-leader Professor Alan Melcher, now Professor of Translational Immunotherapy at the Institute of Cancer Research, London, said:

"Our study establishes a completely new type of viral immunotherapy for the most common primary liver cancer type, hepatocellular carcinoma, which has a very poor prognosis in its advanced form.

"Using a mixture of experiments in human cancer samples and mice, our research showed that the Reovirus therapy switches on the host immune system to attack cancer cells - as well as suppressing the replication of hepatitis C virus, which is linked to many hepatocellular cancers.

"We also showed that Reovirus therapy could be used to treat a range of other cancer types associated with viral infection, including Epstein Barr Virus-associated lymphoma."

Primary liver cancer is cancer that starts in the liver. It is a separate condition from secondary liver cancer, where the cancer originally developed in another part of the body and then spread to the liver.

Most cases of primary liver cancer are associated with damage and scarring of the liver, most commonly from having a hepatitis B or hepatitis C viral infection. Less commonly it is caused by drinking excessive amounts of alcohol over many years.

At least 130 million people globally have chronic hepatitis C infection, according to the World Health Organisation, and a significant proportion of these will develop liver cancer.

Co-researcher Dr Adel Samson from the University of Leeds said: "It is becoming increasingly clear that one of the most powerful weapons available to treat cancer is our own immune system.

"However, as cancers are formed from our own cells, the immune system frequently struggles to identify the subtle differences that differentiate cancerous cells from normal cells, without help.

"Immunotherapy involves various strategies - such as a virus, as in our study - to kick-start our immune system to better identify and fight cancer.

"These 'oncolytic' viruses show great promise in clinical trials, and the first such virus has recently been licensed as a medicine for the treatment of skin cancer."

Dr Justine Alford, senior science information officer at Cancer Research UK which funded the research, said: "This study in cells and mice suggests the possibility of using a harmless oncolytic virus as an immune-boosting one-two punch against liver cancer and the cancer-causing hepatitis C virus.

"These early results also suggest this oncolytic virus could be used more widely in the treatment of virus-driven cancers.

"In these cancers, the viruses can represent a major hurdle for treatment, so we urgently need new and effective ways to tackle the root of the problem.

"The next step will be to see if this technique will work in patients."
-end-
MORE INFORMATION

For a copy of the research paper, or to interview Dr Stephen Griffin, contact the University of Leeds press office on 0113 343 4031 or email pressoffice@leeds.ac.uk

To interview Professor Alan Melcher, contact the Institute of Cancer Research press office on 0207 153 5380.

University of Leeds

Related Cancer Articles from Brightsurf:

New blood cancer treatment works by selectively interfering with cancer cell signalling
University of Alberta scientists have identified the mechanism of action behind a new type of precision cancer drug for blood cancers that is set for human trials, according to research published in Nature Communications.

UCI researchers uncover cancer cell vulnerabilities; may lead to better cancer therapies
A new University of California, Irvine-led study reveals a protein responsible for genetic changes resulting in a variety of cancers, may also be the key to more effective, targeted cancer therapy.

Breast cancer treatment costs highest among young women with metastic cancer
In a fight for their lives, young women, age 18-44, spend double the amount of older women to survive metastatic breast cancer, according to a large statewide study by the University of North Carolina at Chapel Hill.

Cancer mortality continues steady decline, driven by progress against lung cancer
The cancer death rate declined by 29% from 1991 to 2017, including a 2.2% drop from 2016 to 2017, the largest single-year drop in cancer mortality ever reported.

Stress in cervical cancer patients associated with higher risk of cancer-specific mortality
Psychological stress was associated with a higher risk of cancer-specific mortality in women diagnosed with cervical cancer.

Cancer-sniffing dogs 97% accurate in identifying lung cancer, according to study in JAOA
The next step will be to further fractionate the samples based on chemical and physical properties, presenting them back to the dogs until the specific biomarkers for each cancer are identified.

Moffitt Cancer Center researchers identify one way T cell function may fail in cancer
Moffitt Cancer Center researchers have discovered a mechanism by which one type of immune cell, CD8+ T cells, can become dysfunctional, impeding its ability to seek and kill cancer cells.

More cancer survivors, fewer cancer specialists point to challenge in meeting care needs
An aging population, a growing number of cancer survivors, and a projected shortage of cancer care providers will result in a challenge in delivering the care for cancer survivors in the United States if systemic changes are not made.

New cancer vaccine platform a potential tool for efficacious targeted cancer therapy
Researchers at the University of Helsinki have discovered a solution in the form of a cancer vaccine platform for improving the efficacy of oncolytic viruses used in cancer treatment.

American Cancer Society outlines blueprint for cancer control in the 21st century
The American Cancer Society is outlining its vision for cancer control in the decades ahead in a series of articles that forms the basis of a national cancer control plan.

Read More: Cancer News and Cancer Current Events
Brightsurf.com is a participant in the Amazon Services LLC Associates Program, an affiliate advertising program designed to provide a means for sites to earn advertising fees by advertising and linking to Amazon.com.